OPINION
NEWS
REGIONS
WORLD
BUSINESS
SPORTS
ENTERTAINMENT
LIFESTYLE
THE SUNDAY TIMES
SPECIAL FEATURES
SPECIAL SECTIONS
TMT NEWSWIRE
FAST TIMES
LEGAL ADVICE
CAMPUS PRESS
VIDEOS
EXPATS & DIPLOMATS
PHOTOS
BUSINESS FORUM
PODCASTS
RESOURCES
WEATHER
MARKET OVERVIEW
CLASSIFIEDS
EXAM RESULTS
TMT DIGITAL EDITION
TMT CSI
TMT 126TH ANNIVERSARY
QUIZZES
GAMES
Business > Corporate News
Lloyd awaiting approval for anti-Covid drug
By Faye Almazan
Jan 14, 2022 12:09 am

LLOYD Laboratories Inc. on Thursday said they are waiting for the emergency use authorization (EUA) from the Food and Drug Administration (FDA) for the production and distribution of the anti-Covid-19 drug, molnupiravir, in the country.

In a virtual briefing on Thursday, Lloyd business development director Christopher Bamba said they originally applied for a certificate of product registration (CPR) but changed it to an EUA.

Related Articles

Security Bank to buy stake in Home Credit

First Gen unit secures P7-B loan from banks

Megawide to build new Caticlan airport terminal

Globe secures P3-B loan from sister firm

Aboitiz Infra wins bid to upgrade Bohol airport

BDO Capital sees opportunities in growing PH energy investments

NGCP fined P12.3M over delayed projects